Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Solid Biosciences (SLDB)
NASDAQ:SLDB
Holding SLDB?
Track your performance easily
SLDB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.81 - $15.05
Previous Close$7.53
Volume434.55K
Average Volume (3M)486.85K
Market Cap
$290.62M
Enterprise Value$125.65M
Total Cash (Recent Filing)$190.27M
Total Debt (Recent Filing)$25.30M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Nov 07, 2024EPS Estimate
-$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.29
Shares Outstanding38,595,237
10 Day Avg. Volume186,689
30 Day Avg. Volume486,853
Standard Deviation0.34
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.50
Price to Sales (P/S)1020.20
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue418.84
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$17.86Price Target Upside142.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Solid Biosciences News
Bulls Say, Bears Say
Bulls Say
Demand And ExpansionThe demand for the drug significantly outpaced their enrollment plan for the Phase 1/2 study.
Market OpportunityAnalyst recently upgraded SLDB from Market Perform to Outperform based on a clear line of sight to potentially value-creating catalysts for SGT-003 in Duchenne muscular dystrophy.
Safety ProfileThe drug was well tolerated with no serious adverse events or significant elevation of liver enzymes observed.
Bears Say
Durability UncertaintyThe long-term durability of Elevidys in DMD patients remains unknown.
Patient Benefit DoubtsThe jury remains out on whether non-ambulatory patients will materially benefit from Elevidys.
Safety ConcernsSafety for the SGT-003 program has been a considerable overhang for investors leading to the current discounted valuation, given the historical difficulties associated with SLDB's first gene therapy candidate, SGT-001.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $1.81 and its highest was $15.05 in the past 12 months.
What is Solid Biosciences’s market cap?
Currently, no data Available
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Aug 13, 2024. The company reported -$0.61 earnings per share for the quarter, beating the consensus estimate of -$0.664 by $0.054.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -$0.67.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 38,595,238 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.61 in its last earnings report, beating expectations of -$0.664. Following the earnings report the stock price went up 14.54%.
Which hedge fund is a major shareholder of Solid Biosciences?
Among the largest hedge funds holding Solid Biosciences’s share is Perceptive Advisors LLC. It holds Solid Biosciences’s shares valued at 39M.
---
Solid Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.86 (142.01% Upside)
$17.86 (142.01% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 517.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.34%
12-Months-Change
Fundamentals
Return on Equity
-50.81%
Trailing 12-Months
Asset Growth
12.83%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.
---
SLDB Stock 12 Month Forecast
Average Price Target
$17.86
▲(142.01% Upside)
Technical Analysis
Best Analysts Covering SLDB
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-24.75%
reiterated a buy rating last month
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -24.75% per trade.
---